Cytokinetics Inc.(CYTK)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

CYTK iron condor setups CYTK expected move CYTK IV rank history CYTK Fibonacci levels CYTK insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

CYTK $64.66 —
Snapshot
$64.66
52-Week Range
$47.22 – $88.31
YTD
+4.74%
IV Rank (30D)
34.91
Straddle Price
$4.78
P/C Vol Ratio
0.04
Market Cap
$9.1B
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.96%
Beta vs SPY0.89
Cost of Equity (CAPM)9.41% (VRP-adj)
WACC8.89%
Volatility Risk Premium+37.3pp (IV − HV30)
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+30.0%
DCF Horizon10 years explicit + fade
Forward Tilt (NTM/TTM)×1.10 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.6B
Return on Equity (TTM)515.3%
Book / Price-2.1%
Gross Margin (TTM)92.2%
FCF Margin (TTM)-858.2%
Quality Score3/6 — normal (10y DCF)
SMA 50$75.45 (Market Anchor value)
SMA 20 / Bollinger Mid$71.21
Bollinger Width / SMA2024.7% (drives anchor stability)
Net Debt$0.9B
Market Cap$8B
Peers used for multiples: ABBV, BSX, COGT, GILD, JNJ, LLY, MRK, UNH
Model Conviction
70%
20-Day Fair Value
≈ by Oct 26, 2026
$66.46
α +2.8% rank 24%
40-Day Fair Value
≈ by Nov 24, 2026
$73.89
α +14.3% rank 30%
60-Day Fair Value
≈ by Dec 23, 2026
$70.93
α +9.7% rank 34%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 34.6× · 6 peers
Peer EV/EBITDA n/a 0% median 20.0× · 7 peers
Peer P/B n/a 0% median 8.7× · 7 peers
Peer P/S $3.70 18% median 6.2× · 7 peers
Market Anchor (SMA50) $75.45 32% stability 26% (BB-width)
Options Expected (B-L 30d) $65.89 49% 16 strikes · skew +0.34
As of 2026-09-25 · updated
Info
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834)
Exchange
XNAS
Market Cap
$9.1B

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is develo…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
MonthAvg ReturnYears of Data
Jan -1.36% 22
Feb -3.21% 22
Mar -0.16% 22
Apr +1.69% 23
May +2.73% 23
Jun +0.49% 23
Jul +4.65% 23
Aug +3.60% 23
Sep +1.83% 23
Oct -7.21% 22
Nov +1.72% 22
Dec +9.05% 22
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $70.55
SMA 50: $75.14
SMA 200: $70.04
Current: $64.76
EMA 12: $68.47
EMA 26: $71.22
MACD: -2.7501 | Signal: -0.5582
BEARISH
ADX (14): 21.59
WEAK TREND
+DI: 12.28
−DI: 30.57

Momentum Oscillators

RSI (14): 27.50
OVERSOLD
Stoch %K: 6.44
Stoch %D: 5.81
Williams %R: -97.41

Volume & Volatility

BB Upper: $76.63
BB Lower: $64.48
NEUTRAL
OBV: 22,179,799
Vol SMA 20: 2,081,797
Vol ROC: -42.99%
ATR: $2.42
True Range: $1.50
HV 20: 38.5%
HV 30: 35.2%
HV 60: 33.8%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-09-26T00:00:00 – 2026-09-24T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary

Overall Assessment: NEUTRAL (Confidence Level: 6/10)

Key Drivers:

  • Recent positive news headlines highlighting clinical trial results and company announcements
  • Bullish momentum signals from MACD and RSI indicators
  • Moderate volatility, indicating a relatively stable market environment

Primary Risks:

  • Potential for mean reversion if current technical levels are unsustainable
  • Regulatory or clinical trial setbacks that could impact stock performance

Investment Thesis:

Cytokinetics (CYTK) appears to be in a consolidation phase, with recent news headlines and technical indicators suggesting potential upside. The company's Aficamten therapy has shown promising results in clinical trials, which could drive growth prospects. However, the options market is pricing in a relatively low volatility environment, which may not fully capture the stock's potential.

Recent News Sentiment Impact:

The recent positive news headlines have contributed to the bullish sentiment, with the majority of articles highlighting the company's progress and potential for future growth.

Technical Analysis

Trend Direction: Short-term (1-4 weeks) - NEUTRAL

Support/Resistance Levels:

  • SMA 20: $73.41
  • SMA 50: $76.75
  • Upper Bollinger Band: $79.45
  • Lower Bollinger Band: $67.37

Momentum Signals:

  • MACD signal line is below the zero line, indicating bearish momentum (but with a relatively low negative value)
  • RSI is neutral at 35.13%, suggesting no clear overbought or oversold conditions

Volume Analysis:

  • Volume SMA 20: 1955748.80
  • On-Balance Volume (OBV) is increasing, suggesting accumulation
  • Volume Rate of Change is high at 206.53%, indicating strong buying pressure

News & Sentiment Analysis

Recent Headlines Summary:

The past week has seen a series of positive news headlines highlighting the company's progress and potential for future growth.

Sentiment Assessment: POSITIVE (Confidence Level: 8/10)

Catalyst Identification:

  • Upcoming investor conferences
  • Ongoing clinical trials and results announcements

Market Narrative:

The recent news headlines align with the technical signals, suggesting a potential uptrend. However, the MACD signal line is still below the zero line, indicating some caution.

Risk & Volatility Assessment

Beta Interpretation: 0.90 (Moderate risk relative to market)

Volatility Regime: Current vs historical volatility levels - MODERATE

Options Market Signals:

  • IV Rank: 23.1% (Low)
  • Current IV: 64.9%
  • Expected Move: $6.53 (28 DTE), 7-DTE: $1.05
  • Volume Flow: 1,049 calls vs 554 puts
  • Open Interest: 1,378 calls vs 1,126 puts

Downside Protection:

Support levels are relatively strong at the lower Bollinger Band ($67.37) and SMA 20 ($73.41). However, the risk of a technical breakdown is still present.

Market Context & Positioning

Sector Performance: CYTK has outperformed its sector peers over the past month

Institutional Activity:

  • Volume patterns suggest institutional interest in the stock
  • On-Balance Volume (OBV) is increasing, indicating accumulation

Correlation Analysis:

The stock has a moderate correlation with the market (R-squared interpretation), suggesting some independence from broader market trends.

Relative Valuation:

CYTK appears to be trading within its historical range, suggesting no clear overvaluation or undervaluation.

Key Levels & Action Items

Critical Price Levels:

  • SMA 20: $73.41
  • Upper Bollinger Band: $79.45

Breakout/Breakdown Levels:

  • Resistance at the upper Bollinger Band ($79.45)
  • Support at the lower Bollinger Band ($67.37)

Time-Sensitive Catalysts:

  • Upcoming investor conferences
  • Ongoing clinical trials and results announcements

Risk Management:

Consider setting a stop-loss level around $72.50 to manage potential downside risk.

Please let me know if you would like me to elaborate on any of the points or if you have any specific questions!

Generated
Earnings History
7 of 7 under expected move
Avg Expected Move
11.29%
Avg Actual Move
4.10%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2025-02-27 After-Close 16.94% 3.46% 0.20x Within
2025-05-06 After-Close 11.73% 2.84% 0.24x Within
2025-08-07 After-Close 7.09% 3.23% 0.46x Within
2025-11-05 After-Close 10.82% 3.95% 0.37x Within
2026-02-24 After-Close 11.49% 11.43% 0.99x Within
2026-05-05 After-Close 11.66% 0.60% 0.05x Within
2026-08-06 After-Close 9.30% 3.22% 0.35x Within
Options Activity
IV Rank (30D)
34.91
IV Rank (7D)
34.91
Avg IV
73.4%
Straddle (30D)
$4.78
Straddle (7D)
$4.78
P/C Volume
0.04
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
0.89
Correlation (SPY)
25.9%
R²
0.07
Ann. Volatility
44.3%
SPY Volatility
13.0%

Moderate volatility - stock generally follows market

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-06-30
Diluted shares outstanding: 123,861,000 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

508 filers465,834,402 shares$24.98B value376.09% of float
# Filer Shares Value % of Total % of Float Period
1 BlackRock, Inc. Custodian 40,188,724 $3.42B 13.71% 32.45% 2026-06-30
2 VANGUARD GROUP INC Custodian 24,096,262 $1.53B 6.13% 19.45% 2025-12-31
3 WELLINGTON MANAGEMENT GROUP LLP Custodian 17,643,540 $1.19B 4.75% 14.24% 2026-06-30
4 VANGUARD PORTFOLIO MANAGEMENT LLC 13,423,598 $1.14B 4.58% 10.84% 2026-06-30
5 STATE STREET CORP (STT, STT-PG) 12,988,466 $1.11B 4.43% 10.49% 2026-06-30
6 VANGUARD CAPITAL MANAGEMENT LLC 12,235,030 $1.04B 4.17% 9.88% 2026-06-30
7 FMR LLC Custodian 11,668,564 $860.04M 3.44% 9.42% 2026-06-30
8 Avoro Capital Advisors LLC 9,999,998 $851.90M 3.41% 8.07% 2026-06-30
9 BANK OF AMERICA CORP /DE/ Custodian 19,859,418 $807.83M 3.23% 16.03% 2026-06-30
10 GEODE CAPITAL MANAGEMENT, LLC Custodian 7,425,002 $632.65M 2.53% 5.99% 2026-06-30
11 RTW INVESTMENTS, LP 5,724,006 $487.63M 1.95% 4.62% 2026-06-30
12 Polar Capital Holdings Plc 4,507,298 $383.98M 1.54% 3.64% 2026-06-30
13 GOLDMAN SACHS GROUP INC Custodian 6,718,176 $305.57M 1.22% 5.42% 2026-06-30
14 Capital Research Global Investors 3,373,250 $287.37M 1.15% 2.72% 2026-06-30
15 NORTHERN TRUST CORP Custodian 3,294,690 $280.67M 1.12% 2.66% 2026-06-30
16 JPMORGAN CHASE & CO Custodian 3,327,790 $278.54M 1.11% 2.69% 2026-06-30
17 WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 3,206,884 $273.19M 1.09% 2.59% 2026-06-30
18 Integral Health Asset Management, LLC 3,200,000 $272.61M 1.09% 2.58% 2026-06-30
19 Point72 Asset Management, L.P. 3,175,424 $270.51M 1.08% 2.56% 2026-06-30
20 CHARLES SCHWAB INVESTMENT MANAGEMENT INC 3,131,562 $266.78M 1.07% 2.53% 2026-06-30
21 MORGAN STANLEY Custodian 8,101,636 $265.96M 1.06% 6.54% 2026-06-30
22 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian 3,098,916 $264.00M 1.06% 2.50% 2026-06-30
23 PRINCIPAL FINANCIAL GROUP INC 2,623,328 $223.48M 0.89% 2.12% 2026-06-30
24 Capital International Investors 2,611,696 $222.49M 0.89% 2.11% 2026-06-30
25 ARMISTICE CAPITAL, LLC 2,402,684 $204.68M 0.82% 1.94% 2026-06-30
23 filers$1.15B notional
# Filer Notional Value % of Total Period
1 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $322.12M 27.91% 2026-06-30
2 ARMISTICE CAPITAL, LLC $260.68M 22.59% 2026-06-30
3 CITADEL ADVISORS LLC Custodian $154.13M 13.35% 2026-06-30
4 JANE STREET GROUP, LLC Custodian $119.27M 10.33% 2026-06-30
5 Caption Management, LLC $87.30M 7.56% 2026-06-30
6 GROUP ONE TRADING LLC Custodian $64.02M 5.55% 2026-06-30
7 TUDOR INVESTMENT CORP ET AL $22.56M 1.95% 2026-06-30
8 MILLENNIUM MANAGEMENT LLC Custodian $17.06M 1.48% 2026-06-30
9 SILVERBACK ASSET MANAGEMENT LLC $17.04M 1.48% 2026-06-30
10 SPHERA FUNDS MANAGEMENT LTD. $17.04M 1.48% 2026-06-30
11 IMC-Chicago, LLC Custodian $12.52M 1.08% 2026-06-30
12 WOLVERINE TRADING, LLC Custodian $9.68M 0.84% 2025-09-30
13 CITIGROUP INC Custodian $9.54M 0.83% 2026-06-30
14 SIMPLEX TRADING, LLC Custodian $8.50M 0.74% 2026-06-30
15 PEAK6 LLC $7.87M 0.68% 2026-06-30
16 Walleye Trading LLC $7.58M 0.66% 2026-06-30
17 GOLDMAN SACHS GROUP INC Custodian $5.64M 0.49% 2026-06-30
18 BALYASNY ASSET MANAGEMENT L.P. $3.31M 0.29% 2026-06-30
19 JPMORGAN CHASE & CO Custodian $3.05M 0.26% 2026-06-30
20 Walleye Capital LLC $2.47M 0.21% 2026-06-30
21 DLD Asset Management, LP $1.70M 0.15% 2026-06-30
22 Centiva Capital, LP $851.90K 0.07% 2026-06-30
23 HAP TRADING, LLC $288.55K 0.03% 2025-09-30
15 filers$195.54M notional
# Filer Notional Value % of Total Period
1 CITADEL ADVISORS LLC Custodian $71.76M 36.70% 2026-06-30
2 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $49.34M 25.23% 2026-06-30
3 JANE STREET GROUP, LLC Custodian $25.47M 13.03% 2026-06-30
4 LMR Partners LLP $11.40M 5.83% 2026-06-30
5 Walleye Trading LLC $8.96M 4.58% 2026-06-30
6 SIMPLEX TRADING, LLC Custodian $5.42M 2.77% 2026-06-30
7 DIADEMA PARTNERS LP $5.11M 2.61% 2026-06-30
8 TUDOR INVESTMENT CORP ET AL $3.80M 1.94% 2026-06-30
9 BANK OF MONTREAL /CAN/ Custodian $3.41M 1.74% 2026-06-30
10 GROUP ONE TRADING LLC Custodian $3.31M 1.69% 2026-06-30
11 Walleye Capital LLC $2.96M 1.52% 2026-06-30
12 IMC-Chicago, LLC Custodian $2.30M 1.18% 2026-06-30
13 WOLVERINE TRADING, LLC Custodian $2.10M 1.07% 2025-09-30
14 Point72 Asset Management, L.P. $102.23K 0.05% 2026-06-30
15 Persistent Asset Partners Ltd $81.50K 0.04% 2026-06-30
Insider Activity
Latest: 2026-09-22
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-09-22 Fady Ibraham Malik EVP Research & Development Mixed — $38.05 -$211.7K EDGAR
2026-09-15 Robert E Landry Director Sell (S) −1,000 $72.13 -$72.1K EDGAR
2026-09-15 Robert I Blum President & CEO Mixed −99,276 $65.70 -$7.26M EDGAR
2026-09-11 Robert E Landry Director Sell (S) −1,000 $74.66 -$74.7K EDGAR
2026-09-08 Fady Ibraham Malik EVP Research & Development Mixed — $41.63 -$236.8K EDGAR
2026-09-01 B LYNNE PARSHALL Director Sell (S) −5,000 $71.48 -$357.4K EDGAR
2026-08-31 Robert I Blum President & CEO Mixed — $40.42 -$447.3K EDGAR
2026-08-31 Andrew Callos EVP, Chief Commercial Officer Mixed — $46.75 -$469.8K EDGAR
2026-08-18 Fady Ibraham Malik EVP Research & Development Mixed — $41.81 -$238.1K EDGAR
2026-08-10 Robert I Blum President & CEO Mixed — $43.68 -$496.2K EDGAR
2026-07-30 Andrew Callos EVP, Chief Commercial Officer Mixed — $51.57 -$792.7K EDGAR
2026-07-27 Robert I Blum President & CEO Mixed — $45.73 -$527.0K EDGAR
2026-07-23 Fady Ibraham Malik EVP Research & Development Mixed — $44.20 -$254.8K EDGAR
2026-07-16 James M Daly Director Award (A) +151 $82.62 $12.5K EDGAR
2026-07-16 Edward M. MD Kaye Director Award (A) +151 $82.62 $12.5K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
43 insiders · @ $64.76
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Portfolio Services Ltd. 10%+ Owner 2,883,845 $186.76M $12.00M 1 2014-02-27
2 BIOTECHNOLOGY VALUE FUND L P 2,811,818 $182.09M $22.60M 1 2019-12-12
3 Biotechnology Value Trading Fund OS LP 2,777,320 $179.86M $0 1 2020-11-20
4 BVF INC/IL 2,760,185 $178.75M -$77.57M 1 2020-12-11
5 BVF Partners OS Ltd. 2,350,829 $152.24M -$118.47M 1 2020-02-18
6 MICHAEL SCHMERTZLER Director 723,487 $46.85M -$162.9K 16 2010-06-04
7 Robert I Blum President & CEO 475,746 $30.81M -$60.42M 249 2026-09-15
8 Fady Ibraham Malik EVP Research & Development 157,402 $10.19M -$33.03M 156 2026-09-22
9 David Cragg Chief HR & Admin Officer 153,233 $9.92M -$3.80M 36 2022-03-08
10 Jeffrey Hessekiel Chief Legal & Admin Officer 107,943 $6.99M $0 2 2026-03-17
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
Notice of Proposed Sale (Form 144)
Latest: 2026-09-15
Last 30d: 3 filings · $7.6M notice value  ·  Last 90d: 8 filings · $17.4M notice value · 6 unique filers · 88% under 10b5-1 plans

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: ROBERT BLUM (2, $11.6M) · FADY MALIK (1, $2.1M) · ANDREW CALLOS (1, $1.9M) · Sung Lee (2, $1.3M) · B LYNNE PARSHALL (1, $355K)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-09-15 Robert I. Blum President, CEO, Director 97,926 $7.09M 2026-09-15 J.P. Morgan Securities LLC — EDGAR
2026-09-11 ROBERT LANDRY Director 2,000 $147.2K 2026-09-11 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-09-01 B LYNNE PARSHALL Director 5,000 $354.6K 2026-09-01 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-07-30 ANDREW CALLOS Officer 24,000 $1.88M 2026-07-30 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-07-07 FADY MALIK Officer 24,500 $2.10M 2026-07-07 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-07-01 ROBERT BLUM Director, Officer 52,500 $4.47M 2026-07-01 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-06-29 Sung Lee Officer 9,503 $781.1K 2026-06-29 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-06-26 Sung Lee Officer 6,695 $541.0K 2026-06-26 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-06-24 Sung Lee Officer 38,730 $3.10M 2026-06-24 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-06-01 EDWARD KAYE Director 2,933 $225.1K 2026-06-01 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed.
Recent SEC Filings
Latest: 2026-05-27
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Accession Link
2026-05-27 0001193125-26-241840 EDGAR
2026-05-08 0001193125-26-214606 EDGAR
2026-05-05 0001193125-26-206360 EDGAR
2026-05-05 0001193125-26-206420 EDGAR
2026-02-24 0001193125-26-067012 EDGAR
2026-02-17 0001193125-26-053049 EDGAR
2025-12-19 0001193125-25-326778 EDGAR
2025-12-12 0001193125-25-316904 EDGAR
2025-11-14 0001193125-25-282889 EDGAR
2025-11-05 0001193125-25-266842 EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
2026-02-26 0001193125-26-076495 EDGAR
2025-02-27 0000950170-25-029206 EDGAR
2024-02-28 0000950170-24-022256 EDGAR
2023-03-01 0000950170-23-005515 EDGAR
2022-02-25 0001564590-22-007218 EDGAR
2021-02-26 0001564590-21-009467 EDGAR
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-05-05 0001193125-26-206364 EDGAR
2025-11-05 0001193125-25-267059 EDGAR
2025-08-07 0000950170-25-105108 EDGAR
2025-05-06 0000950170-25-064529 EDGAR
2024-11-07 0000950170-24-123283 EDGAR
2024-08-09 0000950170-24-094743 EDGAR
2024-05-10 0000950170-24-057805 EDGAR
2023-11-03 0000950170-23-058914 EDGAR
2023-08-03 0000950170-23-037995 EDGAR
2023-05-05 0000950170-23-018305 EDGAR
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

P/B Ratio-52.7
P/S Ratio135.2
EV/EBITDA-14.4
TTM Revenue$0.1B
TTM Net Income$-0.9B
TTM EPS$-7.22
ROE515.3%
Debt/Equity-6.61